Evidence map›Paper›PMID 38244664›Full record

SynthesisRegulatory toxicology and pharmacology : RTP2024

Systematic update to the mammalian relative potency estimate database and development of best estimate toxic equivalency factors for dioxin-like compounds.

S Fitch, A Blanchette, L C Haws, K Franke, C Ring, M DeVito, M Wheeler, N Walker, L Birnbaum, K I Van Ede and 2 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Regulatory toxicology and pharmacology : RTP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S FitchToxStrategies, Katy, TX, USA. Electronic address: sfitch@toxstrategies.com.
A BlanchetteToxStrategies, Asheville, NC, USA.
L C HawsToxStrategies, Austin, TX, USA.
K FrankeToxStrategies, Asheville, NC, USA.
C RingToxStrategies, Austin, TX, USA.
M DeVitoEnvironmental Protection Agency, Center for Computational Toxicology and Exposure, Research Triangle Park, NC, USA.
M WheelerNational Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, NC, USA.
N WalkerNational Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, NC, USA.
L BirnbaumNational Institute of Environmental Health Sciences, Research Triangle Park, NC, USA; Nicholas School of the Environment, Duke University, Durham, NC, USA.
K I Van EdeKeyToxicology, Arnhem, the Netherlands.
E C Antunes FernandesKeyToxicology, Arnhem, the Netherlands.
D S WikoffToxStrategies, Asheville, NC, USA.

Funding

Intramural EPA EPA999999
6 · The paper itself

Abstract

The World Health Organization (WHO) assesses potential health risks of dioxin-like compounds using Toxic Equivalency Factors (TEFs). This study systematically updated the relative potency (REP) database underlying the 2005 WHO TEFs and applied advanced methods for quantitative integration of study quality and dose-response. Data obtained from fifty-one publications more than doubled the size of the previous REP database (∼1300 datasets). REP quality and relevance for these data was assessed via application of a consensus-based weighting framework. Using Bayesian dose-response modeling, available data were modeled to produce standardized dose/concentration-response Hill curves. Study quality and REP data were synthesized via Bayesian meta-analysis to integrate dose/concentration-response data, author-calculated REPs and benchmark ratios. The output is a prediction of the most likely relationship between each congener and its reference as model-predicted TEF uncertainty distributions, or the 'best estimate TEF' (BE-TEF). The resulting weighted BE-TEFs were similar to the 2005 TEFs, though provide more information to inform selection of TEF values as well as to provide risk assessors and managers with information needed to quantitatively characterize uncertainty around TEF values. Collectively, these efforts produce an updated REP database and an objective, reproducible approach to support development of TEF values based on all available data.

Indexed as

DioxinsPolychlorinated BiphenylsAnimalsBayes TheoremMammalsDioxinsPolychlorinated BiphenylsBayesian meta-analysisDioxinRelative potencyToxic equivalency factors

Identifiers

PMID38244664
PMCPMC11059105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.